Novel Chitosan Derivative as a Systemic Drug Delivery Agent and an Antibiotic Treatment
- Technology Application
- This chitosan derivative may be used to deliver prokaryotic gene silencing CRISPR RNA as a possible treatment for drug resistant infections. Upon acidification, the native chitosan is released. This native chitosan may then damage the bacterial cell membrane and/or interrupt bacterial biological processes by stimulating reactive oxidative species generation. This chitosan/siRNA complex may deliver a one-two punch to combat drug resistant infections.
- Detailed Technology Description
- Proposed uses of chitosan now under research include drug delivery and currently it is used as a topical antibiotic in bandages. However chitosan is a highly insoluble material. Researchers at UCI have modified chitosan with a few hydrophilic functional groups so that the chitosan derivative is more water soluble. This novel chitosan derivative may be used as a systemic drug delivery agent and/or an oral or intravenous antibiotic. Novel siRNAs or other nucleic acids may be complexed with this novel derivative chitosan so the complex may be delivered as a drug therapy to a patient. Upon acidic conditions, the nucleic acid is freed from the complex and the derivative chitosan is hydrolyzed thus releasing chitosan which may act as an antibiotic therapy.
- Application No.
- 9889204
- Others
-
Testing
This chitosan derivative has been tested for its efficiency as a delivery vehicle for pGFP in HeLa cells.
Tech ID/UC Case
24412/2015-035-0
Related Cases
2015-035-0
- *Abstract
-
Researchers at the University of California, Irvine have developed a novel chitosan derivative that may be used simultaneously as a systemic drug delivery agent and a systemic antibiotic treatment.
- *IP Issue Date
- Feb 13, 2018
- *Principal Investigator
-
Name: Julius Edson
Department:
Name: Young Jik Kwon
Department:
- Country/Region
- USA
For more information, please click Here
